- Home
- CURR vs FDMT Comparison
CURR vs FDMT Comparison
Compare CURR & FDMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CURR | FDMT |
|---|---|---|
| Founded | 2013 | 2013 |
| Country | Singapore | United States |
| Employees | 293 | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 500.8M | 449.6M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | CURR | FDMT |
|---|---|---|
| Price | $3.14 | $9.70 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $31.71 |
| AVG Volume (30 Days) | 152.3K | ★ 651.5K |
| Earning Date | 05-19-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 18.79 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $85,209,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $14.56 | $70.28 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 230194.60 |
| 52 Week Low | $0.36 | $3.68 |
| 52 Week High | $4.73 | $12.34 |
Technical Indicators
Market Signals| Indicator | CURR | FDMT |
|---|---|---|
| Relative Strength Index (RSI) | 47.98 | 54.83 |
| Support Level | $2.75 | $9.71 |
| Resistance Level | $3.71 | $10.50 |
| Average True Range (ATR) | 0.32 | 0.80 |
| MACD | -0.01 | 0.04 |
| Stochastic Oscillator | 36.11 | 64.90 |
Price Performance
Historical ComparisonAbout CURR Currenc Group Inc. Ordinary Shares
Currenc Group Inc is a fintech pioneer dedicated to transforming financial services through artificial intelligence (AI). It empowers financial institutions with comprehensive AI solutions, including the SEAMLESS AI Call Centre and other AI-powered tools designed to reduce costs, increase efficiency, and boost customer satisfaction. The Company's digital remittance platform also enables e-wallets, remittance companies, and corporations to provide real-time, 24/7 payment services, advancing financial access across underserved communities. It generates the majority of its geographic revenue from Malaysia.
About FDMT 4D Molecular Therapeutics Inc.
4D Molecular Therapeutics Inc is biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Companies focus is on advancing 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) through late-stage studies. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-710 and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector).